FDA Provides COVID-19 Resources
The agency has added a COVID-19 innovation resource page and an education resources page to its website.
To provide the public with information regarding COVID-19, FDA has created two web pages on its website: "Innovation to Respond to COVID-19" and "Educational Resources". Innovation to Respond to COVID-19 lists FDA’s innovative approaches to respond to COVID-19. It provides updates to connect manufacturers and healthcare entities, analysis of real-world data, the Coronavirus Treatment Acceleration Program, and guidance documents that promote innovation. Educational Resources provides links to COVID-19-related resources that help explain FDA’s work, including videos, a social media kit, consumer articles, and more.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
